ECSP12012033A - Triple combinación para bajar la presión intraocular - Google Patents

Triple combinación para bajar la presión intraocular

Info

Publication number
ECSP12012033A
ECSP12012033A ECSP12012033A ECSP12012033A EC SP12012033 A ECSP12012033 A EC SP12012033A EC SP12012033 A ECSP12012033 A EC SP12012033A EC SP12012033 A ECSP12012033 A EC SP12012033A
Authority
EC
Ecuador
Prior art keywords
intraocular pressure
triple combination
lower intraocular
iop
revealed
Prior art date
Application number
Other languages
English (en)
Inventor
P Pujara Chetan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43743470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012033(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ECSP12012033A publication Critical patent/ECSP12012033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente instrumento se revelan las composiciones para disminuir la presión intraocular (PIO) de un ojo mediante la combinación de agentes que disminuyen la presión intra-ocular (PIO) bimatoprost, brimonidina y timolol. Además se revelan los métodos para reducir la PIO en el ojo de un sujeto.
ECSP12012033 2009-12-22 2012-07-11 Triple combinación para bajar la presión intraocular ECSP12012033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28893609P 2009-12-22 2009-12-22
US36174910P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
ECSP12012033A true ECSP12012033A (es) 2012-10-30

Family

ID=43743470

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012033 ECSP12012033A (es) 2009-12-22 2012-07-11 Triple combinación para bajar la presión intraocular

Country Status (15)

Country Link
US (1) US20130116254A1 (es)
CN (1) CN102695498A (es)
AR (1) AR079696A1 (es)
BR (1) BR112012017319A2 (es)
CL (1) CL2012001736A1 (es)
CO (1) CO6592061A2 (es)
CR (1) CR20120360A (es)
EC (1) ECSP12012033A (es)
GT (1) GT201200213A (es)
IN (1) IN2012DN06416A (es)
MX (1) MX2012007397A (es)
NI (1) NI201200112A (es)
PE (2) PE20121468A1 (es)
TW (1) TW201143773A (es)
WO (1) WO2011087790A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
PL2598119T3 (pl) 2010-07-29 2019-03-29 Allergan, Inc. Niezawierające konserwantów roztwory brymonidyny i timololu
EP2841104A1 (en) 2012-04-24 2015-03-04 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
KR20170129823A (ko) * 2015-03-19 2017-11-27 알러간, 인코포레이티드 브리모니딘 및 티몰롤의 고정된 용량 조합
WO2019246130A1 (en) * 2018-06-19 2019-12-26 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
US20230293541A1 (en) * 2022-03-21 2023-09-21 Somerset Therapeutics, Llc Methods of treating ophthalmic conditions with enhanced penetration compositions of bimatoprost and timolol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution

Also Published As

Publication number Publication date
AR079696A1 (es) 2012-02-15
CO6592061A2 (es) 2013-01-02
WO2011087790A1 (en) 2011-07-21
MX2012007397A (es) 2012-08-15
US20130116254A1 (en) 2013-05-09
TW201143773A (en) 2011-12-16
NI201200112A (es) 2013-04-09
CR20120360A (es) 2012-07-30
PE20121468A1 (es) 2012-10-28
GT201200213A (es) 2014-08-29
PE20160904A1 (es) 2016-09-16
CL2012001736A1 (es) 2012-10-12
CN102695498A (zh) 2012-09-26
IN2012DN06416A (es) 2015-10-09
BR112012017319A2 (pt) 2016-04-19

Similar Documents

Publication Publication Date Title
ECSP12012033A (es) Triple combinación para bajar la presión intraocular
JO3039B1 (ar) طريقة ومركب لعلاج فرط ضغط العين والجلوكوما
MX358176B (es) El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.
MY175318A (en) Androgen composition for treating an opthalmic condition
MX2012003759A (es) Metodos y composiciones para tratamiento de fibrosis ocular.
NZ597626A (en) Bicyclic compound and use thereof for medical purposes
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
CO6571924A2 (es) Combinaciòn, kit y mètodo para reducir la presión intraocular
MX2012012941A (es) Nuevas composiciones oftalmicas.
GT200600277A (es) Derivados de prostaglandina
CR20130094A (es) Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular
CL2012002612A1 (es) Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma.
CL2012002613A1 (es) Metodo para reducir la presion intraocular que comprende suministrar un compuesto n6- ciclopentiladenosina a la camara anterior de un ojo afectado; compuestos derivados de n6- ciclopentiladenosina; composicion farmaceutica oftalmica que los comprende; y su uso para reducir la presion intraocular.
BRPI0512525A (pt) canabidióis anormais como agentes para diminuir a pressão intraocular e fornecer efeito neuroprotetor ao olho
BR112012010795A2 (pt) Formulações oftálmicas contendo gama lactams substituídas e métodos para uso das mesmas
MX2012005447A (es) Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.
AR081411A1 (es) Composiciones quirurgicas que contienen agonistas de los receptores sigma
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
UA70475U (ru) Способ прогнозирования риска прогрессирования возрастной макулодистрофии после ультразвуковой факоэмульсификации возрастной катаракты
ECSP034742A (es) Combinacion de brimonidina y timolol para uso oftalmologico topico
UA66343U (ru) Способ диагностики вторичной глаукомы на глазах с измененной роговицей
TH128998B (th) การใช้โพสตาแกลนดิน (prostaglandins) F2 อัลฟ่า และสารอะนาล็อก สำหรับการรักษาเยียวยารอยโรคที่เกี่ยวกับกระจกตา (corneal) และเยื่อหุ้มตาขาว (conjunctival)
GR1008250B (el) Οφθαλμικο σκευασμα αναλογου προσταγλανδινης και μεθοδος παρασκευης αυτου
UA34515U (ru) Способ улучшения оптических свойств глаза